|
Nafamostat (mesylate) | 甲磺酸萘莫司他
MCE 国际站:Nafamostat (mesylate)
中文名:甲磺酸萘莫司他
CAS:82956-11-4
品牌:MedChemExpress (MCE)
存储条件:4°C, sealed storage, away from moisture and light
生物活性: Nafamostat mesylate 是一种合成的丝氨酸蛋白酶抑制剂,是一种抗凝剂。 Nafamostat mesylate 通过降低颗粒酶活性和 CTL 细胞溶解来抑制 T 细胞自身反应性。萘莫司他甲磺酸盐可阻断 SARS-CoV-2 的激活。[1][2][3][4]。 IC50 和目标:丝氨酸蛋白酶[1][2]。颗粒酶[3]。
体外:Nafamostat mesylate (10-80 μg/mL, 3-48 h) 通过阻断 IκBα 磷酸化抑制 MDAPanc-28 细胞 NF-κB 活性[1]。 Nafamostat mesylate (80 μg/mL, 24-48 h) 通过上调肿瘤坏死因子受体 1 (TNFR1) 的表达诱导 MDAPanc-28 细胞凋亡[1]。 Nafamostat mesylate (0.1-10 μM, 24 h) 对 Panc-1 细胞的侵袭能力有抑制作用[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内:Nafamostat mesylate (10 mg/kg,腹腔注射,一天一次,持续 18 天) 对寨卡病毒 (ZIKV) 感染的 A129 小鼠具有良好的抗病毒作用[3]。 Nafamostat mesylate (0.5-2.0 mg/mL (溶于生理盐水中),腹腔注射,一天一次,连续 7 天) 对大鼠颈动脉壁球囊损伤后新生内膜形成有抑制作用[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: A129 mice[3] Dosage: 10 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Exhibit delayed lethality and improved survival (40%). Animal Model: Balloon injury of the rat carotid wall [4] Dosage: 0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline) Administration: Intraperitoneal injection (i.p.) Result: Showed smaller ratios of the neointima/medial area. Showed positive but reduced immunoreactivity of the cells in the neointimal. Clinical Trial
热销产品:Ribavirin | Belinostat | DBCO-amine | SAICAR | Ulixertinib | KU-55933 | Adenosine 5'-diphosphate | DBCO-(PEG)3-VC-PAB-MMAE | Carfilzomib | Alectinib
研究领域:Anti-infection | Apoptosis | NF-κB | Metabolic Enzyme/Protease
作用靶点:Flavivirus | TNF Receptor | NF-κB | Apoptosis | Ser/Thr Protease
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献:[1]. Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109(10): 2142-2153.
[2]. Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94(5): 699-704.
[3]. Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.
[4]. Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30(3): 644-650.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-15 04:29
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社